SoFi CEO enters prepaid forward contract on 1.5 million shares
BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a biopharmaceutical company specializing in personalized cancer treatments, announced on Thursday that it has regained compliance with the Nasdaq's minimum bid price requirement. The Nasdaq Stock Market's Office of General Counsel confirmed that Allarity's stock maintained a closing bid price of $1.00 or more for 20 consecutive trading days since September 11, 2024.
Thomas Jensen, CEO of Allarity Therapeutics, expressed satisfaction with the company's return to compliance, which allows it to continue focusing on its stenoparib program. The Phase 2 trial of stenoparib in advanced ovarian cancer has been producing encouraging data. Jensen highlighted the urgency of developing new treatments for advanced ovarian cancer patients, who currently have limited options.
Stenoparib is an orally available inhibitor that targets both PARP1/2 and Tankyrase 1 and 2. Its potential as a cancer therapy is linked to its ability to inhibit PARP and block Wnt pathway activation, a pathway often associated with the progression of various cancers. Allarity holds exclusive global rights to develop and commercialize stenoparib, which was initially developed by Eisai Co (OTC:ESAIY). Ltd.
Allarity Therapeutics, headquartered in the U.S. with a research facility in Denmark, is committed to addressing unmet medical needs in cancer treatment. The company is currently using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial (NCT03878849) for stenoparib.
The press release includes forward-looking statements regarding the clinical progress and potential benefits of stenoparib, as well as the company's strategy for advancing regulatory approval processes based on trial data. However, these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
The information provided is based on a press release statement and does not include any endorsement of claims. It is intended to report developments regarding Allarity Therapeutics' compliance status with Nasdaq and the ongoing development of its cancer treatment program.
In other recent news, Allarity Therapeutics has made significant strides in its Phase 2 clinical trial for stenoparib, a novel therapy for advanced recurrent ovarian cancer. The company announced that two patients have surpassed one year of treatment, a noteworthy achievement considering the patients' pre-treatment conditions. Allarity Therapeutics is actively planning to advance the stenoparib program towards regulatory approval, with updates expected in the coming months.
In parallel, Allarity has implemented strategic changes in its operations and financial strategies. The company has expanded its At-The-Market agreement with Ascendiant Capital Markets, increasing the potential sale of company shares to $50 million. Furthermore, Alexander Epshinsky has been appointed as the new CFO, replacing Joan Y. Brown.
The company also executed a 1-for-30 reverse stock split of its common stock, a move aimed at regaining compliance with Nasdaq's listing requirements. Additionally, amendments to the company's Certificate of Incorporation were approved, decreasing the number of authorized shares of common stock from 750 million to 250 million.
Allarity's stockholders also approved an amendment to the Allarity Therapeutics Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for grant from approximately 2.2 million to over 10.5 million. These recent developments are part of Allarity's ongoing efforts to advance its pipeline of cancer therapies.
InvestingPro Insights
While Allarity Therapeutics (NASDAQ: ALLR) has regained compliance with Nasdaq's minimum bid price requirement, recent market data from InvestingPro reveals some challenging financial metrics for the company. As of the last twelve months ending Q2 2024, Allarity reported an adjusted operating income of -$16.92 million, indicating ongoing financial pressures despite its progress in clinical trials.
InvestingPro Tips highlight that Allarity is currently trading near its 52-week low and has experienced significant price declines across various timeframes. The stock's price has fallen by 99.63% over the past year, which aligns with the company's focus on regaining Nasdaq compliance and its ongoing efforts to develop stenoparib.
It's worth noting that Allarity holds more cash than debt on its balance sheet, potentially providing some financial flexibility as it continues its clinical programs. However, the company is not profitable over the last twelve months, which is consistent with many biopharmaceutical companies in the development stage.
For investors interested in a deeper analysis, InvestingPro offers 14 additional tips for Allarity Therapeutics, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.